The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Utilizing Genomic Assays for Decision Making in Early Stage Breast Cancer

Adam M. Brufsky, MD, PhD
Published Online: 2:06 PM, Wed July 19, 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the utility of molecular signatures in managing early-stage breast cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.